AP NEWS

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Neuromyelitis Optica (Devic s Syndrome) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects.The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 6, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

IntroductionOverviewTherapeutics DevelopmentTherapeutics AssessmentCompanies Involved in Therapeutics DevelopmentDrug ProfilesDormant ProjectsDiscontinued ProductsProduct Development Milestones

Companies Featured

Abide Therapeutics Inc.Acer Therapeutics Inc.Alexion Pharmaceuticals Inc.Biogen Inc.Bionure Farma SLBoston Pharmaceuticals Inc.Chugai Pharmaceutical Co. Ltd.Endece LLCHanAll Biopharma Co. Ltd.LFB SATolerion Inc.Vicore Pharma AB

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lhqptx/neuromyelitis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005458/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 10:41 AM/DISC: 09/17/2018 10:41 AM

http://www.businesswire.com/news/home/20180917005458/en

AP RADIO
Update hourly